Profile data is unavailable for this security.
About the company
Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Company’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, pre-clinical SERCA2a activators for heart failure and VAR-101 and VAR-102, pre-clinical precision atypical protein kinase C iota (aPKCi) inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum, enhancing calcium reuptake from the cytoplasm. It also has a licensing business model with partnership out-licenses in place.
- Revenue in USD (TTM)0.00
- Net income in USD-20.29m
- Incorporated1992
- Employees15.00
- LocationWindtree Therapeutics Inc2600 Kelly Rd Ste 100WARRINGTON 18976-3652United StatesUSA
- Phone+1 (215) 488-9300
- Fax+1 (215) 488-9301
- Websitehttps://windtreetx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNS Pharmaceuticals Inc | 0.00 | -18.85m | 2.35m | 3.00 | -- | -- | -- | -- | -5.76 | -5.76 | 0.00 | -0.7132 | 0.00 | -- | -- | 0.00 | -255.54 | -132.47 | -1,018.78 | -185.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.42 | -- | -- | -- |
| PaxMedica Inc | 0.00 | -18.29m | 2.37m | 6.00 | -- | 0.6931 | -- | -- | -15.85 | -15.85 | 0.00 | 0.4574 | 0.00 | -- | -- | 0.00 | -463.93 | -755.77 | -915.89 | -- | -- | -- | -- | -- | -- | -1,760.66 | 0.00 | -- | -- | -- | -23.56 | -- | -- | -- |
| Salarius Pharmaceuticals Inc | 0.00 | -12.54m | 2.39m | 2.00 | -- | 0.3732 | -- | -- | -4.54 | -4.54 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -118.12 | -69.27 | -160.07 | -79.89 | -- | -- | -- | -675.70 | -- | -- | 0.0519 | -- | -- | -- | 60.32 | -- | -- | -- |
| Resonate Blends Inc | 16.47k | -1.42m | 2.41m | 6.00 | -- | -- | -- | 146.58 | -0.0178 | -0.0178 | 0.0002 | -0.0247 | 0.0237 | -- | -- | -- | -203.52 | -680.29 | -- | -- | -593.02 | -78.88 | -8,597.33 | -12,895.26 | -- | -0.4691 | 7.89 | -- | -66.73 | -56.57 | -316.63 | -- | -- | -- |
| 60 Degrees Pharmaceuticals Inc | 253.57k | -3.99m | 2.43m | 3.00 | -- | -- | -- | 9.58 | -0.6657 | -0.6657 | 0.0456 | 0.8382 | 0.0559 | 0.9638 | 1.83 | 84,523.34 | -84.00 | -- | -- | -- | -87.15 | -- | -1,504.04 | -- | 2.39 | -1.89 | 0.0321 | -- | -50.40 | -- | 35.51 | -- | -- | -- |
| Sonoma Pharmaceuticals Inc | 12.31m | -5.08m | 2.43m | 9.00 | -- | 0.319 | -- | 0.1978 | -0.9608 | -0.9608 | 1.95 | 0.489 | 0.8625 | 2.58 | 4.76 | 1,367,778.00 | -35.56 | -37.52 | -47.14 | -51.35 | 39.17 | 40.17 | -41.23 | -37.12 | 3.11 | -- | 0.0065 | -- | 5.10 | -4.44 | -1.28 | -- | 7.54 | -- |
| Agile Therapeutics Inc | 19.59m | -14.47m | 2.51m | 19.00 | -- | -- | -- | 0.128 | -9.84 | -9.84 | 9.11 | -5.51 | 1.60 | 4.41 | 5.79 | 1,031,158.00 | -118.12 | -94.24 | -- | -142.62 | 54.18 | -- | -73.85 | -513.50 | 0.3269 | -- | -- | -- | 80.02 | -- | 43.08 | -- | -- | -- |
| Windtree Therapeutics Inc | 0.00 | -20.29m | 2.52m | 15.00 | -- | 8.74 | -- | -- | -8.21 | -8.21 | 0.00 | 0.5655 | 0.00 | -- | -- | 0.00 | -57.68 | -44.51 | -63.50 | -48.38 | -- | -- | -- | -94,533.34 | -- | -- | 0.8179 | -- | -- | -- | 48.25 | -- | -- | -- |
| Qrons Inc | 0.00 | -789.36k | 2.53m | 2.00 | -- | -- | -- | -- | -0.0581 | -0.0581 | 0.00 | -0.109 | 0.00 | -- | -- | 0.00 | -45,235.53 | -1,513.45 | -- | -- | -- | -- | -- | -- | -- | -5.76 | -- | -- | -- | -- | -7.61 | -- | -- | -- |
| American Green Inc | -100.00bn | -100.00bn | 2.57m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| DSwiss Inc | 1.47m | -49.54k | 2.59m | 11.00 | -- | 45.84 | 157.51 | 1.76 | -0.0002 | -0.0002 | 0.0071 | 0.0003 | 3.92 | 154.82 | 54.81 | 133,643.60 | -13.22 | -8.69 | -50.26 | -45.47 | 24.44 | 25.55 | -3.37 | -2.47 | 1.05 | -15.74 | 0.3961 | -- | -20.50 | 46.20 | -688.36 | -- | -66.17 | -- |
| Virpax Pharmaceuticals Inc | 0.00 | -15.19m | 2.62m | 7.00 | -- | 1.36 | -- | -- | -12.97 | -12.97 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -103.68 | -87.52 | -164.09 | -116.56 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.84 | -- | -- | -- |
| cbdMD Inc | 23.45m | -23.98m | 2.62m | 52.00 | -- | 0.9759 | -- | 0.112 | -20.34 | -20.34 | 12.19 | 0.8839 | 0.9227 | 2.06 | 23.44 | 450,876.20 | -78.62 | -38.59 | -101.68 | -41.50 | 63.84 | 63.80 | -85.21 | -87.98 | 0.6383 | -9.92 | 0.00 | -- | -31.77 | 120.91 | 63.64 | -- | -4.95 | -- |
| GB Sciences Inc | 0.00 | -4.03m | 2.64m | 3.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0119 | 0.00 | -- | -- | 0.00 | -255.86 | -49.16 | -- | -131.40 | -- | 6.03 | -- | -995.19 | -- | -8.63 | -- | -- | -- | -- | -2,715.25 | -- | -60.82 | -- |
| SYBLEU Inc | 11.70k | -307.88k | 2.68m | -- | -- | -- | -- | 229.39 | -0.0293 | -0.0293 | 0.0011 | -0.0367 | 0.0641 | -- | -- | -- | -168.63 | -- | -- | -- | -- | -- | -2,631.45 | -- | -- | -8.48 | 4.96 | -- | 0.00 | -- | 26.51 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Windtree Therapeutics Inc's reporting currency: US Dollar USD
3.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Alyeska Investment Group LPas of 31 Dec 2023 | 136.52k | 1.61% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 41.64k | 0.49% |
| Virtu Americas LLCas of 31 Dec 2023 | 38.88k | 0.46% |
| Citadel Securities LLCas of 31 Dec 2023 | 38.13k | 0.45% |
| Geode Capital Management LLCas of 31 Dec 2023 | 14.20k | 0.17% |
| UBS Securities LLCas of 31 Dec 2023 | 501.00 | 0.01% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Dec 2023 | 32.00 | 0.00% |
| UBS Financial Services, Inc.as of 31 Dec 2023 | 9.00 | 0.00% |
| U.S. Bank NA (Cincinnati Ohio Investment Management)as of 31 Dec 2023 | 3.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 2.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
